

SEQUENCE LISTING

<110> Niles, Andrew L
Haak-Frendscho, Mary
Harris, Jennifer L
Craig, Charles S

<120> Trypsin Substrates and Assay For Trypsin Activity Using Same

<130> 34506.xxx

<140> Filed Herewith

<141> 2001-09-19

<150> 60/244,013

<151> 2000-10-27

<160> 23

<170> PatentIn version 3.1

<210> 1

<211> 4

<212> PRT

<213> Synthetic polypeptide

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 is Arg (R) or Lysine (K)

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa at position 3 is any amino acid

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 is Arg (R) or Lys (K)

<400> 1

Pro Xaa Xaa Xaa

1

<210> 2

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 2

Pro Arg Asn Lys

1

<210> 3

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 3

Pro Lys Asn Lys

1

<210> 4

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 4

Pro Arg Asn Arg

1

<210> 5

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 5

Pro Lys Asn Arg

1

<210> 6

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 6

Pro Ala Asn Lys

1

<210> 7

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 7

Pro Arg Thr Lys

1

<210> 8

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 8

Pro Arg Phe Lys

1

<210> 9

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 9

Thr Arg Leu Arg

1

<210> 10

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 10

Ser Lys Gly Arg

1

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

<221> MOD_RES
 <222> (4)..(4)
 <223> K at position 4 is modified to contain a C-terminal 7-amino-4-carbamoylmethyl-coumarin group

<400> 12

Pro Arg Asn Lys
 1

<210> 13
 <211> 4
 <212> PRT
 <213> Synthetic polypeptide

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> P at position 1 is modified to include an N-terminal acetyl group

<400> 13

Pro Arg Asn Lys
 1

<210> 14
 <211> 4
 <212> PRT
 <213> Synthetic polypeptide

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> P at position 1 is modified to include an N-terminal acetyl group

<220>
 <221> MOD_RES
 <222> (4)..(4)

<223> K at position 4 is modified to include a C-terminal chloromethyl ketone group

<400> 14

Pro Arg Asn Lys

1

<210> 15

<211> 4

<212> PRT

<213> Synthetic polypeptide

<220>

<221> MOD_RES

<222> (1)..(1)

<223> P at position 1 is modified to include an N-terminal acetyl group

<220>

<221> MOD_RES

<222> (4)..(4)

<223> K at position 4 is modified to include a C-terminal 7-amino-4-carbamoylmethyl-coumarin group

<400> 15

Pro Arg Asn Lys

1

<210> 16

<211> 4

<212> PRT

<213> Synthetic polypeptide

<220>

<221> MOD_RES

<222> (1)..(1)

<223> P at position 1 is modified to include an N-terminal acetyl group

<220>

<221> MOD_RES

<222> (4)..(4)

<223> K at position 4 is modified to include a C-terminal 7-amino-4-carbamoylmethyl-coumarin group

<400> 16

Pro Arg Thr Lys

1

<210> 17

<211> 4

<212> PRT

<213> Synthetic polypeptide

<220>

<221> MOD_RES

<222> (1)..(1)

<223> P at position 1 is modified to include an N-terminal acetyl group

<220>

<221> MOD_RES

<222> (4)..(4)

<223> K at position 4 is modified to include a C-terminal 7-amino-4-carbamoylmethyl-coumarin group

<400> 17

Pro Arg Asn Arg

1

<210> 18

<211> 4

<212> PRT

<213> Synthetic polypeptide

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<220>
 <221> MOD_RES
 <222> (4)..(4)
 <223> N-METHYLATION

<400> 18

Pro Arg Asn Lys

1
 <210> 19
 <211> 4
 <212> PRT
 <213> Synthetic polypeptide

<400> 19

Pro Arg Phe Lys

1
 <210> 20
 <211> 4
 <212> PRT
 <213> Synthetic polypeptide

<400> 20

Ile Arg Ser Lys

1
 <210> 21
 <211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 21

Ser Lys Gly Arg

1

<210> 22

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 22

Phe Arg Thr Lys
1

<210> 23

<211> 4

<212> PRT

<213> Synthetic polypeptide

<400> 23

Ile Lys Thr Lys
1